Bayer has appointed Nelson Ambrogio as its new head of radiology business in its pharmaceuticals division. The appointment will begin April 1.
Ambrogio will serve on Bayer's pharmaceuticals executive committee and be based in Berlin, Germany; he will report to Stefan Oelrich, who is a member of the company's board of management and president of its pharmaceuticals division. Ambrogio replaces Gerd Krueger, who led the radiology unit of the division for eight years.
Ambrogio has most recently served as senior vice president and general manager of Bayer’s U.S. oncology business, Bayer said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
